Expert Insights

A subset of patients with PV will pose challenges

Read transcript Close transcript

If you go back in the literature, and you can go back into the early ‘60s and just come forward, what you’re gonna find repeatedly is that there is a segment of polycythemia vera patients, and it’s a minimum of 10%—it might be 15%—that have a more aggressive disease, but the rest of the patients do not. And what we did very simply was we said we interrogated what genes are these stem cells making. And we could divide polycythemia vera patients into 2 groups: those who are gonna do well and those who are gonna do poorly. People who do badly, their stem cells are making a different set of genes than the people who do well. And that is immutable data, that is, genetic data.

head shot of Dr Spivak
Jerry Spivak, MD Professor of Medicine and Oncology Director Center for the Chronic Myeloproliferative Disorders Johns Hopkins University School of Medicine | Baltimore, MD
Dr Jerry Spivak is a researcher and professor of medicine and oncology at Johns Hopkins University School of Medicine. He has served as a member and director on multiple boards, including the International Society of Hematology, and has been published in over 230 scientific and clinical journals. Among the awards Dr Spivak has received are a Research Career Development Award and a Merit Award from the National Institutes of Health.